Braidwell LP Has $10.55 Million Stock Position in Vor Biopharma Inc. $VOR

Braidwell LP boosted its position in Vor Biopharma Inc. (NASDAQ:VOR) by 22.8% during the 2nd quarter, Holdings Channel reports. The fund owned 573,104 shares of the company’s stock after buying an additional 106,330 shares during the period. Braidwell LP’s holdings in Vor Biopharma were worth $10,551,000 as of its most recent SEC filing.

A number of other hedge funds have also recently added to or reduced their stakes in VOR. Renaissance Technologies LLC purchased a new position in shares of Vor Biopharma during the first quarter valued at approximately $2,298,000. UBS Group AG raised its position in Vor Biopharma by 284.8% in the 4th quarter. UBS Group AG now owns 292,118 shares of the company’s stock valued at $3,821,000 after buying an additional 216,209 shares during the last quarter. Frazier Life Sciences Management L.P. purchased a new stake in Vor Biopharma in the 4th quarter valued at $33,275,000. NEXTBio Capital Management LP bought a new position in Vor Biopharma during the 4th quarter valued at $13,080,000. Finally, Bank of America Corp DE lifted its stake in Vor Biopharma by 28,408.1% during the 1st quarter. Bank of America Corp DE now owns 112,892 shares of the company’s stock valued at $2,014,000 after acquiring an additional 112,496 shares in the last quarter. Institutional investors and hedge funds own 97.29% of the company’s stock.

Vor Biopharma Price Performance

Shares of NASDAQ:VOR opened at $24.76 on Thursday. The company’s 50-day moving average is $20.92 and its 200 day moving average is $16.93. Vor Biopharma Inc. has a fifty-two week low of $6.50 and a fifty-two week high of $49.95.

Vor Biopharma (NASDAQ:VOR) last posted its quarterly earnings data on Tuesday, August 11th. The company reported ($0.80) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.69) by ($0.11). On average, analysts predict that Vor Biopharma Inc. will post -2.56 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several research firms recently weighed in on VOR. HC Wainwright restated a “buy” rating and set a $31.00 price target on shares of Vor Biopharma in a report on Monday, May 18th. Weiss Ratings raised shares of Vor Biopharma from a “sell (d-)” rating to a “sell (d+)” rating in a research report on Tuesday, August 11th. Wall Street Zen upgraded Vor Biopharma from a “sell” rating to a “hold” rating in a research note on Saturday, August 15th. Finally, Wedbush upped their target price on Vor Biopharma from $18.00 to $27.00 and gave the company a “neutral” rating in a report on Wednesday, August 12th. Two equities research analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $43.38.

Vor Biopharma Profile

Vor Biopharma, Inc is a clinical-stage biotechnology company focused on the development of next-generation, allogeneic cell therapies for patients with hematologic malignancies. The company’s proprietary platform leverages genome editing to engineer donor-derived hematopoietic stem cells (HSCs), enabling the generation of off-the-shelf therapeutic candidates designed to overcome limitations of traditional autologous and matched donor transplants. By targeting key surface antigens and reconstituting the patient’s immune system, Vor aims to deliver curative potential with reduced treatment timelines and broader patient applicability.

The lead program, VOR33, is a CD33-edited HSC product candidate being evaluated in relapsed or refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS).